Navigation Links
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Date:9/23/2008

SAN DIEGO, Sept. 23 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Douglas B. Muchmore, MD, has joined the company as Vice President, Endocrinology Clinical Development.

"I am thrilled to welcome an individual of Dr. Muchmore's high caliber and achievement to the Halozyme leadership team. He is a widely respected endocrinologist for his talent and experience in drug development, clinical medicine, and regulatory interaction in academic, research, and corporate settings. Doug's addition to Halozyme will immediately add value to the advancement of our insulin and bisphosphonate programs," said Jonathan Lim, MD, President and CEO of Halozyme Therapeutics. "His decision to join Halozyme further validates the quality of our research programs, the promise of our technology, and the exciting potential of our ongoing product development efforts. Doug Muchmore exemplifies Halozyme's steadfast commitment to attract, develop, and retain top talent with extensive experience in each of our therapeutic disciplines and in all functional areas of the company."

Dr. Muchmore has more than 30 years of professional experience in clinical drug development, clinical research trial design and implementation, and the practice of endocrinology. His experience spans all stages of clinical development in the field of endocrinology, where he has direct experience with diabetes and osteoporosis indications. Prior to joining Halozyme, Dr. Muchmore served as Medical Fellow II on the Insulins and Devices Team and a member of the Diabetes Platform Team at Eli Lilly and Co. He acted as the key scientific develope
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... A long-term retrospective study of breast ... via interstitial brachytherapy suggests that women younger than ... be suitable to receive the treatment. Current American ... patients in the "unsuitable" category for APBI. In ... Beaumont Health System,s Peter Y. Chen , ...
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... developing targeted therapeutic devices to address infectious disease, cancer ... Sciences, Inc. (ESI), disclosed today that each company will ... Summit. On September 18 th , ... presentation entitled: "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... JH Technologies announces the grand opening ... JH Technologies, a leader in sales and support of ... partnership with Leica Microsystems into the Southern California market. ... will be featured at the grand opening slated for ... is located within the JH Technologies office’s at 18025 ...
(Date:9/17/2014)... 2014 Intarcia Therapeutics, Inc. today ... study of the cost and predictability of non-adherence in ... Annual Meeting of the European Association for the Study ... Christian Frois , Ph.D., of Analysis Group, Inc. presented ... Intarcia-sponsored, retrospective studies to characterize the prevalence of non-adherence ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... to Accelerate Workflow, CHICAGO, Nov. 27 ... the MAMMOMAT(R) Novation S, a new,digital mammography ... at the 93rd Scientific Assembly and Annual ... (RSNA) from Nov. 25 to 30 at,McCormick ...
... of Health, Labor and Welfare (MHLW), for the revolutionary ... ... the blood, IRVINE, Calif., Nov. 27 Masimo, the ... today announced approval of the Masimo Rad-57 Pulse CO-Oximeter,bringing the ...
... UCLA,s California NanoSystems Institute, the David Geffen School of ... have modeled the structure of the largest cellular particle ... drug delivery. , The research study, ... as a drug-therapy vehicle, appears in the Nov. 27 ...
Cached Biology Technology:Siemens Unveils New Digital Mammography System for Optimized Screening 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 3Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 4Researchers outline structure of largest nonvirus particle ever crystallized 2
(Date:9/17/2014)... a new crime unit designed to fight food fraud ... horse meat being passed off as beef scientists ... adulteration. They describe their approach, which represents a vast ... Agricultural and Food Chemistry . , Hans-Ulrich Humpf and ... economic problem. But they also say that adding, for ...
(Date:9/16/2014)... for Children,s Environmental Health at the Mailman School of ... between childhood asthma and prenatal exposure to two phthalates ... appear online in the journal Environmental Health Perspectives ... pregnancy to higher levels of the chemicals, butylbenzyl phthalate ... and 78 percent increase in risk of developing asthma ...
(Date:9/16/2014)... September, 2014)More than $100 trillion in cumulative public ... carbon dioxide (CO2)a 40 percent reduction of urban ... the world expands public transportation, walking and cycling ... by the University of California, Davis, and the ... , Further, an estimated 1.4 million early deaths ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... Wireless ... for Emergency Responders, WALL, N.J., Oct. 15 BIO-key ... and wireless public safety solutions, today announced that,it will be ... Chiefs of Police (IACP) Conference and,Exposition, October 15-17 at the ...
... (AD) is a progressive neurodegenerative disorder characterized by ... amyloid plaques and neurofibrillary tangles. Neuronal and synaptic ... occur in specific brain areas involved in memory ... cerebral deposition of A" plays a seminal role ...
... to ramp up testosterone production appears to drive male ... comes with an evolutionary cost. Big fluctuations in testosterone ... their own young, scientists have learned. In ... Indiana University Bloomington, University of Virginia and University of ...
Cached Biology News:BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 2BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 3Paradigm shift in Alzheimers's research: new treatments 2Paradigm shift in Alzheimers's research: new treatments 3Paradigm shift in Alzheimers's research: new treatments 4Testosterone turns male juncos into blustery hunks -- and bad dads 2Testosterone turns male juncos into blustery hunks -- and bad dads 3
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Biology Products: